Javier B. Szwarcberg - 11 Dec 2025 Form 4 Insider Report for SPRUCE BIOSCIENCES, INC. (SPRB)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ Samir Gharib, Attorney-in-Fact
Issuer symbol
SPRB
Transactions as of
11 Dec 2025
Net transactions value
$0
Form type
4
Filing time
15 Dec 2025, 18:52:04 UTC
Previous filing
12 Dec 2025
Next filing
05 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Szwarcberg Javier B. CHIEF EXECUTIVE OFFICER, Director C/O SPRUCE BIOSCIENCES, INC., 611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO /s/ Samir Gharib, Attorney-in-Fact 15 Dec 2025 0001903669

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SPRB Employee Stock Option (right to buy) Award +10,000 10,000 11 Dec 2025 Common Stock 10,000 $104.13 Direct F1, F2, F3
transaction SPRB Employee Stock Option (right to buy) Disposed to Issuer -10,000 -100% 0 11 Dec 2025 Common Stock 10,000 $344.25 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the stock option vest over a four-year period commencing January 3, 2022, with 1/4th of the shares vested on January 3, 2023 and 1/36th of the remaining shares vesting on a monthly basis, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan).
F2 The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date.
F3 Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options.